Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Southwestern Scale Announces Expansion Into Texas Business
  • Zayed Law Offices Ranked by Best Law Firms in 2024 World News
  • Questions raised over safety of planned Rosatom nuclear power plants in Uzbekistan. Business
  • Exploring the Global Electric Guitars Market World News
  • Korean Sports Broadcasting Platform Exit Touches New Heights Business
  • Secretary Blinken’s Meeting with Trinidad and Tobago’s Foreign Minister Browne World News
  • Mandel JCC of the Palm Beaches Launches Hiring Initiative for Preschool Teachers Business
  • 31 ADHD Stories in 31 Days with Award-Winning Journalist and TV/Radio Personality Lindsay Guentzel and ADHD Online Business

New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria

Posted on March 15, 2023September 7, 2026 By NewsEditor
New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With ProgeriaNew Progerin Biomarker Predicts Survival Benefits of Treatment in Children With ProgeriaBiomarker has future applications in new drug candidate identification and could be used in broader cardiovascular and aging-related research.

New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria
PRF Logo

The Progeria Research Foundation logo

PEABODY, Mass., March 15, 2023 (Newswire.com) - A newly developed progerin biomarker indicates long-term benefit of treatment in children with Progeria is greater than previously determined, according to a study in an advanced online publication in the journal Circulation today. The study, led by Progeria Research Foundation (PRF) co-founder and Medical Director Dr. Leslie Gordon, found that lower progerin levels in the blood samples reflected survival benefit, and a longer duration of time spent on lonafarnib (Zokinvy™) treatment was associated with an even greater increase in life expectancy than previously understood. 

Progerin is the toxic protein that causes Progeria, an ultra-rare, fatal pediatric rapid-aging disease. Progerin is found in all people but is generated at much higher levels in children and young adults with Progeria. With this new biomarker blood test, researchers can now measure the progerin level in any person at any given time—helping scientists understand how treatments are affecting clinical trial participants after only a few months on treatment and at multiple points along each clinical trial. To better understand progerin's connection to adult heart disease and the general aging process, additional studies will be necessary.

The progerin biomarker can optimize the clinical trial process by providing early information about the effectiveness of progerin-targeted treatments as a lead-in to clinical measures that can demonstrate changes later in the course of therapy. This may provide the opportunity to detect treatment benefits as early as four months after starting treatment, or stop a treatment that may not be beneficial and avoid unnecessary treatment side effects.

The study used data from the PRF International Patient Registry and blood samples from the PRF Cell and Tissue Bank, which contains samples donated from the clinical trials co-coordinated by PRF and Boston Children's Hospital (BCH). In patients with Progeria, lonafarnib (Zokinvy) lowered progerin levels by about 35 - 62 percent for as long as the children stayed on the drug. The longer a child stayed on the drug, the greater the survival benefit from being on therapy. Life expectancy for patients on treatment for 10 years was estimated to increase by almost 5 years. 

Trial design decides how much such data can carry. Multi Academic Journal explains how randomisation and blinding actually work in a trial.

PRF's next step is to submit the biomarker data to the FDA for their critical evaluation as a validated test that can be used for measuring treatment effects and for new drug approvals.

"Measuring this new progerin biomarker from a blood sample means we can move faster towards finding better treatments and the cure for children with Progeria," said Dr. Leslie Gordon, The Progeria Research Foundation's co-founder and Medical Director. "Future treatment strategies that we are developing for Progeria, including small molecules, RNA therapeutics and DNA base editing, will all benefit greatly from this discovery." 

"We're thrilled that this study data estimates more than a 35% increase in lifespan for those who've taken lonafarnib for 10 years," said Audrey Gordon, Executive Director of The Progeria Research Foundation. "Every day, we at PRF are working toward our mission of finding new treatments and the cure. Today's announcement marks another major step closer to that goal."

"After conducting Progeria-related clinical trials at Boston Children's Hospital, where we've enrolled children from over 20 countries, having a biomarker is an exciting milestone," said Dr. Monica Kleinman, Principal Investigator for the Progeria clinical trials at Boston Children's Hospital. "We hope that following progerin levels gives us an earlier indication as to whether a trial treatment is working for children with this ultra-rare disease." 

About The Progeria Research Foundation

The Progeria Research Foundation (PRF) was established in 1999 by the family of Sam Berns, a child with Progeria. Within four years of its founding, the PRF Genetics Consortium discovered the Progeria gene, a collaboration led by Dr. Francis Collins, White House Science Advisor and former Director of the National Institutes of Health (NIH). As of 2007, PRF has funded and co-coordinated all Progeria clinical trials conducted at Boston Children's Hospital and supports scientists who conduct Progeria research worldwide. PRF's International Patient Registry includes over 370 children with Progeria in 70 countries. 

PRF is the only nonprofit organization solely dedicated to finding treatments and the cure for Progeria and its aging-related conditions, including heart disease. The organization fills a void, putting these children and Progeria at the forefront of scientific efforts. For more information and to support PRF's mission, please visit www.progeriaresearch.org. 

Contact Information:
Eleanor Maillie
Communications Manager, PRF
[email protected]
978.879.9244


Original Source: New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria

The post New Progerin Biomarker Predicts Survival Benefits of Treatment in Children With Progeria first appeared on Social Gov.

Business

Post navigation

Previous Post: Industry Leaders Launch NeXus Digital Group
Next Post: Dynamic Media Introduces Comprehensive 2023 Background Music Buyer’s Guide

Related Posts

  • How Activation Agencies Navigate Winter Months Business
  • Wilson Learning Named to 2023 Training Industry Top 20 Sales Training and Enablement Companies List for the 15th Consecutive Year Business
  • KaJ Labs Launches  Billion Web3, AI Grant Program for Lithosphere (LITHO) & Jot Art (JOT) Developers
    KaJ Labs Launches $1 Billion Web3, AI Grant Program for Lithosphere (LITHO) & Jot Art (JOT) Developers Business
  • WOMEN’S MONTH AND GENDER EQUAILTY ALSO MEANS ADVOCATING FOR FINANCIAL FREEDOM FOR WOMEN
    WOMEN’S MONTH AND GENDER EQUAILTY ALSO MEANS ADVOCATING FOR FINANCIAL FREEDOM FOR WOMEN Business
  • The Souk in San Ramon Sold to Private Equity Firm Business
  • ReoStar Signs LOI With L. Myers Associates for Acquisition Business
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Comprehensive Astigmatism Market Report Includes Forecasts, Innovations, and Industry InsightsNovember 21, 2026
  • SEOPS Secures Stoke Space’s Nova Launch Capacity for Waymaker ProgramNovember 21, 2026
  • Ataxia Market Analysis Report Exploring Demand Patterns and Competitive LandscapeNovember 20, 2026
  • SEOPS Expands Waymaker Rideshare Program with Third Falcon 9 Launch with SpaceXNovember 20, 2026
  • The Assistive Technologies Market for Visually Impaired Expected to Reach $12.71 Billion by 2030November 19, 2026
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Auto2x ranks Automotive Suppliers by Readiness in Level 4 Autonomous Driving Business
  • Questions raised over safety of planned Rosatom nuclear power plants in Uzbekistan. Business
  • War Day 237: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 237: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • CORRECTION: Wheels Up Founding Chief Growth Officer and Global Brand Ambassador, Stephanie Chung, Joins Washington Speakers Bureau’s Exclusive Speakers Roster: Available for Bookings Business
  • Air Defense System Market Anticipated to Grow at 6.08% CAGR Through 2030: Industry Report World News
  • Regal Investments Launches Crypto Prop Trading Platform Ahead of CEOlympics Business
  • LTV Ukraine War Chronicles. Day 722 pt1: Who Are Russians?  – Latynina.tv – Alexey Arestovych
    LTV Ukraine War Chronicles. Day 722 pt1: Who Are Russians? – Latynina.tv – Alexey Arestovych World News
  • Secretary Blinken Participates in a Conversation at the University of Chicago’s Institute of Politics World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2026 195 News. All Rights Reserved by Coolaser

Powered by .